Journal Watch · European Heart Journal · 2026
Plasma infrared molecular fingerprinting stratifies residual risk in coronary artery disease and reflects clonal haematopoiesis-associated biology.
IMF offers a scalable phenotypic platform for precision secondary prevention and biology-guided trial design.
TL;DR
IMF offers a scalable phenotypic platform for precision secondary prevention and biology-guided trial design.
Key findings
- IMF-derived risk strata showed clear separation of Kaplan-Meier survival curves (log-rank P < .001), with mortality increasing from 3% (low-risk) to 27% (high-risk).
- Higher-risk strata were enriched for CHIP carriers, particularly spliceosome mutations.
- External validation reproduced expected risk patterns and comorbidity associations.<h4>Conclusions</h4>Plasma IMF provides rapid, low-cost, sequencing-free assessment of residual mortality risk in CAD, outperforming guideline-based scores while reflecting CHIP-associated biology.
- IMF offers a scalable phenotypic platform for precision secondary prevention and biology-guided trial design.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Penalized Cox models using IMF features were benchmarked against the guideline-recommended SMART2 score. Model performance was assessed by discrimination, reclassification, calibration, and decision curve analyses. External validation was performed in three independent cohorts (PRECAD2, 474 individuals; KORA, 3044 individuals; Lasers4Life, 2123 individuals).<h4>Results</h4>IMF+Age demonstrated superior mortality discrimination over SMART2 (C-index 0.79 vs 0.74, P < .01) and significant reclassification improvement. Decision curves showed greater net benefit across clinical thresholds.
Full abstract (original)
Background: <h4>Background and aims</h4>Residual cardiovascular risk remains substantial in patients with coronary artery disease (CAD) despite optimal secondary prevention. Clonal haematopoiesis of indeterminate potential (CHIP) contributes causally to this risk but requires sequencing for detection. Plasma infrared molecular fingerprinting (IMF), a spectroscopy-based assay, was evaluated as a sequencing-free tool for residual risk stratification and CHIP-aligned phenotyping.<h4>Methods</h4>The discovery cohort included 1341 patients with angiographically confirmed CAD (mean age 73 years, 76% male) followed for up to 10.7 years. Plasma IMF spectra, comprehensive clinical data, and targeted sequencing of 13 CHIP driver genes were measured.
What they did: Penalized Cox models using IMF features were benchmarked against the guideline-recommended SMART2 score. Model performance was assessed by discrimination, reclassification, calibration, and decision curve analyses. External validation was performed in three independent cohorts (PRECAD2, 474 individuals; KORA, 3044 individuals; Lasers4Life, 2123 individuals).<h4>Results</h4>IMF+Age demonstrated superior mortality discrimination over SMART2 (C-index 0.79 vs 0.74, P < .01) and significant reclassification improvement. Decision curves showed greater net benefit across clinical thresholds.
Results & conclusions: IMF-derived risk strata showed clear separation of Kaplan-Meier survival curves (log-rank P < .001), with mortality increasing from 3% (low-risk) to 27% (high-risk). Higher-risk strata were enriched for CHIP carriers, particularly spliceosome mutations. External validation reproduced expected risk patterns and comorbidity associations.<h4>Conclusions</h4>Plasma IMF provides rapid, low-cost, sequencing-free assessment of residual mortality risk in CAD, outperforming guideline-based scores while reflecting CHIP-associated biology. IMF offers a scalable phenotypic platform for precision secondary prevention and biology-guided trial design.
Abstract © the authors / European Heart Journal (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/eurheartj/ehag587 · PubMed 42522903.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking European Heart Journal for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this European Heart Journal study find?
IMF offers a scalable phenotypic platform for precision secondary prevention and biology-guided trial design.
What type of study is this?
It is a cohort / observational clinical study, published in European Heart Journal in 2026. Penalized Cox models using IMF features were benchmarked against the guideline-recommended SMART2 score.
Where can I read the original paper?
The original is at the publisher via DOI 10.1093/eurheartj/ehag587. PubMed ID: 42522903. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/plasma-infrared-molecular-fingerprinting-stratifies-residual-risk-in-cor-hag587/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides